ArticleJournal of translational medicine2026
Gut microbiota-driven hippuric acid hydrolysis promotes pancreatic tumorigenesis by suppressing NK cell activity.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by a lack of effective early detection, profoundly immunosuppressive microenvironment, and poor responsiveness to current therapies. Emerging evidence suggests that gut microbiota and their metabolites play important roles in pancreatic tumorigenesis. Glycoproteins shed from pancreatic precancerous lesions may influence the composition of the gut microbiota and their metabolites.
methodsWe established a pancreatic precancerous lesion mouse model and performed integrated fecal metagenomic sequencing and non-targeted metabolomic profiling to characterize microbiota composition and metabolite alterations. Further we use plasma samples from patients, in vitro cytotoxicity assays and in vivo orthotopic pancreatic tumor models, fecal microbiota transplantation and pancreatic homogenate gavage to assess the effect of microbiota and metabolite alterations. And we conduct RNA sequencing, qPCR, ELISA, flow cytometry, molecular docking, and surface plasmon resonance to further explore its mechanisms.
resultsWe identified hippuric acid as a key microbiota-derived metabolite that was significantly reduced during pancreatic tumorigenesis, which was associated with suppressed anti-tumor immunity and enhanced PDAC progression. This reduction was associated with enrichment of microbiota harboring hippurate hydrolase and correlated with poor prognosis in PDAC patients. Mechanistically, hippuric acid activated IL-21R-STAT3-TBX21 signaling axis, promoting the expression of cytotoxic effector molecules, including granzyme B and perforin, thus enhancing NK cell cytotoxicity. Molecular docking and surface plasmon resonance analyses further suggested a direct interaction between hippuric acid and IL-21R.
conclusionsCollectively, our study uncovers a previously unrecognized positive feedback regulatory loop involving the PDAC-gut microbiota-hippuric acid-NK cell-PDAC axis and highlights the critical role of gut microbiota and their metabolites in pancreatic tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.